

DURECT to Present at the Rodman & Renshaw Global Healthcare Conference

CUPERTINO, Calif., May 13, 2010 /PRNewswire via COMTEX/ –DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Rodman & Renshaw Global Healthcare Conference on Monday, May 17 at 4:30 p.m. London time (11:30 am Eastern Time). The conference is being held at the Grosvenor House Hotel in London.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing www.wsw.com/webcast/rrshq17/drrx.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation